Entry Point Capital, LLC Axsome Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 437 shares of AXSM stock, worth $37,245. This represents 0.03% of its overall portfolio holdings.
Number of Shares
437Holding current value
$37,245% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding AXSM
# of Institutions
291Shares Held
37.1MCall Options Held
401KPut Options Held
464K-
Rtw Investments, LP New York, NY4.49MShares$383 Million5.75% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$319 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.2MShares$272 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$201 Million30.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.3MShares$111 Million3.44% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $3.65B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...